Dose-Response Relationship, Drug

"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The relationship between the dose of an administered drug and the response of the organism to the drug.

Descriptor ID	D004305
MeSH Number(s)	G07.690.773.875 G07.690.936.500
Concept/Terms	Dose-Response Relationship, Drug Dose-Response Relationship, Drug Dose-Response Relationships, Drug Drug Dose-Response Relationship Drug Dose-Response Relationships Relationship, Drug Dose-Response Relationships, Drug Dose-Response Dose Response Relationship, Drug

Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".

Biological Sciences [G]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacological Phenomena [G07.690.773]
Dose-Response Relationship, Drug [G07.690.773.875]
Toxicological Phenomena [G07.690.936]
Dose-Response Relationship, Drug [G07.690.936.500]

Below are MeSH descriptors whose meaning is related to "Dose-Response Relationship, Drug".

Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".

Dose-Response Relationship, Drug
Hormesis
Lethal Dose 50

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.

Bar chart showing 699 publications over 30 distinct years, with a maximum of 63 publications in 2003

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	0	2	2
1994	0	1	1
1995	0	1	1
1996	0	2	2
1997	0	4	4
1998	0	2	2
1999	0	3	3
2000	0	10	10
2001	0	5	5
2002	0	41	41
2003	0	63	63
2004	0	52	52
2005	0	49	49
2006	0	44	44
2007	0	46	46
2008	1	56	57
2009	0	49	49
2010	0	42	42
2011	0	35	35
2012	0	26	26
2013	0	30	30
2014	0	27	27
2015	0	20	20
2016	0	15	15
2017	0	30	30
2018	0	17	17
2019	0	15	15
2020	0	7	7
2021	0	3	3
2022	0	1	1

Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.

Brose MS, Panaseykin Y, Konda B, de la Fouchardiere C, Hughes BGM, Gianoukakis AG, Joo Park Y, Romanov I, Krzyzanowska MK, Leboulleux S, Binder TA, Dutcus C, Xie R, Taylor MH. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2022 02 17; 107(3):776-787.

View in: PubMed
Ippolito M, De Pascali F, Inoue A, Benovic JL. Phenylalanine 193 in Extracellular Loop 2 of the ß2-Adrenergic Receptor Coordinates ß-Arrestin Interaction. Mol Pharmacol. 2022 02; 101(2):87-94.

View in: PubMed
Albert CM, Cook NR, Pester J, Moorthy MV, Ridge C, Danik JS, Gencer B, Siddiqi HK, Ng C, Gibson H, Mora S, Buring JE, Manson JE. Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial. JAMA. 2021 03 16; 325(11):1061-1073.

View in: PubMed
Turakhia M, Sundaram V, Smith SN, Ding V, Michael Ho P, Kowey PR, Piccini JP, Foody J, Birmingham MC, Ianus J, Rajmane A, Mahaffey KW. Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial. Am Heart J. 2021 07; 237:68-78.

View in: PubMed
Webster GF, Sugarman J, Levy-Hacham O, Toledano O. Microencapsulated Benzoyl Peroxide and Tretinoin for the Treatment of Acne Vulgaris: Results from a Phase 2 Multicenter, Double-Blind, Randomized, Vehicle-Controlled Study. Skinmed. 2020; 18(6):343-351.

View in: PubMed
Klein KO, Freire A, Gryngarten MG, Kletter GB, Benson M, Miller BS, Dajani TS, Eugster EA, Mauras N. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty. J Clin Endocrinol Metab. 2020 10 01; 105(10).

View in: PubMed
Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020 09; 19(9):727-737.

View in: PubMed
Kwok CS, Wong CW, Nagaraja V, Mamas MA. A systematic review of the studies that evaluate the performance of the DAPT score. Int J Clin Pract. 2020 Oct; 74(10):e13591.

View in: PubMed
Li Z, Radin A, Li M, Hamilton JD, Kajiwara M, Davis JD, Takahashi Y, Hasegawa S, Ming JE, DiCioccio AT, Li Y, Kovalenko P, Lu Q, Ortemann-Renon C, Ardeleanu M, Swanson BN. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. Clin Pharmacol Drug Dev. 2020 08; 9(6):742-755.

View in: PubMed
Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of Cataract Development among Children with Juvenile Idiopathic Arthritis-Related Uveitis Treated with Topical Corticosteroids. Ophthalmology. 2020 04; 127(4S):S21-S26.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement